for people ages 18 years and up (full criteria)
study started
estimated completion
Principal Investigator
by Bartosz Chmielowski, MD (ucla)



The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.

Official Title

A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.


This is a two-part, open-label, multi-center, dose escalation and dose expansion study in participants with BRAF mutation-positive and/or NRAS mutation-positive tumors designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of KIN-2787, a RAF small molecule kinase inhibitor, to determine a recommended Phase 2 dose (RP2D) of KIN-2787, and to assess the objective response to KIN-2787 therapy alone and in combination with binimetinib, a mitogen-activated protein kinase (MEK) inhibitor. The dose expansion phase (Part B) will assess the safety and efficacy of KIN-2787 at the recommended dose and schedule in patients with cancers that contain BRAF Class II or III mutations, including lung cancer, melanoma, and other selected solid tumors.


Solid Tumor, Adult Non-small Cell Lung Cancer Melanoma BRAF inhibitor BRAF pan-RAF pan-RAF inhibitor RAF1 ARAF BRAF alteration BRAF Class II BRAF Class III V600 tumor growth inhibitor (TGI) NSCLC solid tumor targeted therapy BRAF Class I NRAS Metastatic Unresectable CRC ATC Colon Thyroid Advanced KIN-2787 KIN-2787 and binimetinib


You can join if…

Open to people ages 18 years and up

  • Provide written informed consent prior to initiation of any study-specific procedures.
  • Metastatic or advanced stage solid tumor
  • Known BRAF Class I, Class II, or Class III alteration or melanoma with an NRAS mutation as confirmed by previous genomic analysis of tumor tissue or ctDNA.
  • Measurable or evaluable disease by RECIST v1.1.
  • ECOG performance status 0, 1, or 2.
  • Adequate organ function, as measured by laboratory values (criteria listed in protocol).
  • Able to swallow, retain, and absorb oral medications.

You CAN'T join if...

  • Known clinically-active or clinically-progressive brain metastases from non-brain tumors.
  • In Part B Dose Expansion, previous treatment with any approved or in-development small molecule BRAF-, MEK-, or MAPK-directed inhibitor therapy.
  • GI tract disease causing an inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, or uncontrolled inflammatory GI disease.
  • Active, uncontrolled bacterial, fungal, or viral infection.
  • Participant with a positive test result for SARS-CoV2 infection, is known to have asymptomatic infection or is suspected of having SARS-CoV2, is excluded
  • Women who are lactating or breastfeeding, or pregnant.
  • In Part B Dose Expansion, patients with BRAF Class I mutations are excluded.

Complete inclusion and exclusion criteria are listed in the clinical study protocol.


  • UCSD Moores Cancer Center accepting new patients
    La Jolla California 92093 United States
  • UCLA accepting new patients
    Los Angeles California 90095 United States
  • University of Southern California accepting new patients
    Los Angeles California 90033 United States
  • City of Hope accepting new patients
    Duarte California 91010 United States
  • Stanford Cancer Center accepting new patients
    Stanford California 94305 United States

Lead Scientist at University of California Health

  • Bartosz Chmielowski, MD (ucla)
    HS Clinical Professor, Medicine. Authored (or co-authored) 114 research publications


accepting new patients
Start Date
Completion Date
Kinnate Biopharma
Phase 1 research study
Study Type
Expecting 155 study participants
Last Updated